Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

POLA-R-GEMOX regimen is a promising option for relapsed/refractory diffuse...

Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA

$POLA-R-GEMOX regimen is a promising option for relapsed/refractory diffuse large B-cell lymphoma ( Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA )$

(Bio) Markers and milestones at the crossroads of mHSPC care 

Dr Miguel Ramírez-Backhaus, Prof Jozefina Casuscelli, Prof Gerhardt Attard

(Bio) Markers and milestones at the crossroads of mHSPC care  ( Dr Miguel Ramírez-Backhaus, Prof Jozefina Casuscelli, Prof Gerhardt Attard )

Challenging the status quo: Unlocking new horizons for patients with HR-NMIBC...

Prof Bernardo Hererra Imbroda and Dr Géraldine Pignot

Challenging the status quo: Unlocking new horizons for patients with HR-NMIBC after BCG treatment ( Prof Bernardo Hererra Imbroda and Dr Géraldine Pignot )

Encorafenib/binimetinib/nivolumab combo improves PFS in BRAF-mutant melanoma...

Dr Zeynep Eroglu - Moffitt Cancer Center, Tampa, USA

Encorafenib/binimetinib/nivolumab combo improves PFS in BRAF-mutant melanoma brain metastases ( Dr Zeynep Eroglu - Moffitt Cancer Center, Tampa, USA )

Enhanced pathologic response with neoadjuvant pembrolizumab plus vidutolimod in...

Dr Ahmad Tarhini - Moffitt Cancer Center, Tampa, USA

Enhanced pathologic response with neoadjuvant pembrolizumab plus vidutolimod in high-risk resectable melanoma ( Dr Ahmad Tarhini - Moffitt Cancer Center, Tampa, USA )

ASCO 2025: Importance of early testing in metastatic prostate cancer

Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida...

ASCO 2025: Importance of early testing in metastatic prostate cancer ( Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida Maiorano )

HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC

Dr David Braun - Yale School of Medicine, New Haven, USA

HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC ( Dr David Braun - Yale School of Medicine, New Haven, USA )

Catequentinib improves PFS vs placebo in advanced or metastatic leiomyosarcoma

Prof Robin Lewis Jones - The Royal Marsden, London, UK

Catequentinib improves PFS vs placebo in advanced or metastatic leiomyosarcoma ( Prof Robin Lewis Jones - The Royal Marsden, London, UK )

Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial...

Dr Brigida Maiorano - IRCCS San Raffaele Hospital, Milan, Italy

Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial bladder cancer ( Dr Brigida Maiorano - IRCCS San Raffaele Hospital, Milan, Italy )

Ropeginterferon Alfa-2b shows superior efficacy over anagrelide in essential...

Dr Ruben A. Mesa - Atrium Health Wake Forest Baptist Comprehensive Cancer...

Ropeginterferon Alfa-2b shows superior efficacy over anagrelide in essential thrombocythaemia ( Dr Ruben A. Mesa - Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, USA )

ASCO 2025: Latest updates in mRCC

Dr Michael Serzan, Dr Guillermo De Velasco, Dr Alessandro Rametta and Dr Javier...

ASCO 2025: Latest updates in mRCC ( Dr Michael Serzan, Dr Guillermo De Velasco, Dr Alessandro Rametta and Dr Javier Puente )

New MOAs in prostate cancer treatment - what’s next?

Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini

New MOAs in prostate cancer treatment - what’s next? ( Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini )

More from ecancer